ADAM17 and neoplasm: Thus, a higher ADAM17 expression or activity in ascites-derived cells (UF354-ascites) compared with tumor derived cells (UF-354-tumor) could explain the stronger responsiveness of these cells to combination therapy using ADAM17 inhibitor GW280264X and cisplatin compared with cisplatin-only treatment.